What are your guys initial thoughts on this company
R
A revolution in cancer care if favorable results are confirmed.
m
Huge potential for $NTNX , 30$ target by beginning of 2021
M
news out yesterday, see nanobiotix website: - Combo therapy including augmented anti-tumor response in both irradiated and unirradiated (abscopal) tumors, improving local and distant tumor control, and increasing survival rate - Survivor mice were immune to re-injections of tumor cells, maintained significantly higher percentages of memory immune cells and stronger anti-tumor immune activities than control
PARIS & CAMBRIDGE, Mass., November 09, 2021--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the "Company"), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients w
PARIS & CAMBRIDGE, Mass., November 09, 2021--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the "Company"), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients w
finance.yahoo.com
Y
NBTX is down 10.28% to 17.05
Y
NBTX is up 12.00% to 18.48
M
first time there is some volume on this stock in the US. is it going to move at last?
Y
NBTX is up 11.45% to 18.50
Y
Nanobiotix is up 6.94% to 14.68
S
Asco Poster Abstracts are out. Some impressive response data in HNSCC....
Y
Nanobiotix is up 10.06% to 18.00
l
NANOBIOTIX Reports New Data for NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure:
- Combo therapy including augmented anti-tumor response in both irradiated and unirradiated (abscopal)
tumors, improving local and distant tumor control, and increasing survival rate
- Survivor mice were immune to re-injections of tumor cells, maintained significantly higher percentages of
memory immune cells and stronger anti-tumor immune activities than control
What do you think about bridge to CAR T therapy?
https://www.businesswire.com/news/home/20210603005997/en/NANOBIOTIX-Reports-New-Data-for-Potential-First-in-Class-Radioenhancer-NBTXR3-in-Combination-With-Anti-PD-1-Showing-Local-or-Distant-Tumor-Regression-in-76.9-of-Evaluable-Patients-Regardless-of-Prior-Anti-PD-1-Exposure